SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2026)

SAB Biotherapeutics (SABS) has 3 years of Change in Interest Receivables data on file, last reported at $608280.0 in Q1 2026.

• Quarterly Change in Interest Receivables rose 1912.03% year-over-year to $608280.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 992.47% YoY) and the FY2025 annual result came in at $891826.0, up 1522.83% from the prior year.
• Change in Interest Receivables climbed to $608280.0 in Q1 2026, from $386827.0 in the prior quarter.
• In the past five years, Change in Interest Receivables ranged from a high of $608280.0 in Q1 2026 to a low of -$127877.0 in Q3 2024.
• A 3-year average of $172784.6 and a median of $31692.0 in 2024 frame the typical range for Change in Interest Receivables.
• Annual changes were most pronounced in 2025 — Change in Interest Receivables plunged 167.48% — and 2026, when it soared 1912.03%.
• Tracing SABS's Change in Interest Receivables over 3 years: stood at -$42092.0 in 2024, then jumped by 1019.0% to $386827.0 in 2025, then surged by 57.25% to $608280.0 in 2026.
• The last three Change in Interest Receivables figures came in at $608280.0 (Q1 2026), $386827.0 (Q4 2025), and $559954.0 (Q3 2025), per Business Quant data.